Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

New recommendations on urticaria care promises to ease primary care management

Pank Jit Sin
19 Nov 2018

The handbook is a collaboration between the Malaysian Urticaria Expert Group (mARTeg), Malaysian Society of Allergy and Immunology (MSAI) and Dermatological Society of Malaysia (PDM); and is sponsored by Menarini. In the book, healthcare professionals (HCPs) can expect to find an easy-to-understand and comprehensive handbook including topics such as diagnosis of urticaria, management of urticaria in adults and children; and case studies involving adult and paediatric patients. The book is authored by Drs Chang Choong Chor, Kent Woo, Lee Yin Yin, Leong Kin Fon, Pubalan Muniandy and Tang Jyh Jong.

According to the foreword penned by the book’s editors Dr Adrian Yong and Dr Amir Hamzah, mARTeg was formed in May 2017 under the auspices of PDM and MSAI. The group consists of eminent members from both the fields of dermatology and immunology. The group was formed with the aim of optimizing management of urticaria, in terms of safety and efficacy, in the country; promoting awareness of urticaria among healthcare professionals and patients; adapting management of urticaria to local populations; and identifying knowledge gaps which may impact urticaria care in the local setting. The group’s discussions and publications contributed largely to the publication of the urticaria management handbook.

HCPs interested in obtaining the handbook can get in touch with Menarini Asia Pacific at (03)-7985 7100 or at their website https://www.menariniapac.com/contact-us#EnquiryForm-div.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.